N-Gene
About N-Gene
N-Gene is a developer of clinical-stage bio-pharmaceutical drugs designed to focus on the discovery, development, and commercialization of proprietary synthetic small molecules. The company's drugs use proprietary synthetic small molecule BGP-15 that has been found efficacious in various indications relating to adverse metabolic conditions, including type 2 diabetes mellitus by blocking JNK phosphorylation and has a new therapeutic effect via stress response modulation, enabling pharmaceutical companies to get a series of synthetic molecules to treat the insulin-resistance syndrome, improve cancer chemotherapy, and slow skin aging.
Company Metrics
- Employees: 11-50
- Monthly Visits: None
- Tech Stack: None active products
Financial Information
- Estimated Revenue:
- Total Funding: 3000000 USD
- Last Funding: None (Private Equity)
- Funding Status: Private Equity
Technology Stack
N-Gene actively uses None products in their tech stack.
Market Presence
Industries: Biotechnology, Pharmaceutical
Headquarters: Szentistván, Borsod-Abauj-Zemplen, Hungary